Drug Approval | January 13, 2022
South Korea approves Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Launching in 2022, its availability will be expanded to the global market
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
